Igand JL. Hydroxymethylglutarylcoenzyme a reductase inhibition promotes endothelial nitric oxide synthase activation by means of a reduce in caveolin abundance. Tempo Biological Activity Circulation 2001; 103: 1138. Pelat M, Dessy C, Massion P, Desager JP, Feron O, Balligand JL. Rosuvastatin decreases caveolin1 and improves nitric oxidedependent heart price and blood pressure variability in apolipoprotein E/ mice in vivo. Circulation 2003; 107: 24806.[25][45][26][46] [47][27][28][48] [49] [50][29][30][51] [52][31][53] [54][32][33] [34] [35][55] [56][57][36][58][37][59][38][60] [61][39][62] [63][40][41][64][42] [43][65][44]Lipid Raft in Cardiac Well being and Disease [66] Febbraio M, Podrez EA, Smith JD, et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 2000; 105: 104956. Podrez EA, Febbraio M, Sheibani N, et al. Macrophage scavenger receptor CD36 will be the key receptor for LDL modified by monocytegenerated reactive nitrogen species. J Clin Invest 2000; 105: 1095108. Diwan A, Dorn GW. Decompensation of cardiac hypertrophy: cellular mechanism and novel therapeutic target. Physiology 2007; 22: 5664. Hill JA, Karimi M, Kutschke W, et al. Cardiac hypertrophy is just not a essential compensatory response to brief term pressure overload. Circulation 2000; 101: 28632869. Sano M, Schneider MD. Still stressed out but doing fine: normalization of wall strain is superfluous to sustain cardiac function in chronic stress overload. Circulation 2002; 105: 810. Koga A, Oka N, Kikuchi T, Miyazaki H, Kato S, Imaizumi T. Adenovirusmediated overexpression of caveolin3 inhibits rat cardiomyocyte hypertrophy. Hypertension 2003; 42: 2139. Fujita T, Otsu K, Oshikawa J, et al. Caveolin3 inhibits development signal in cardiac myoblasts inside a Ca2dependent manner. J Cell Mol Med 2006; ten: 21624. De Souza AP, Cohen AW, Park DS, et al. MR imaging of caveolin genespecific alterations in ideal ventricular wall thickness. Magn Reson Imaging 2005; 23: 618. Ohsawa Y, Toko H, Katsura M, et al. Overexpression of P104L mutant caveolin3 in mice develops hypertrophic cardiomyopathy with enhanced contractility in association with enhanced endothelial nitric oxide synthase activity. Hum Mol Genet 2004; 13: 15157. Wunderlich C, Schober K, Lange SA, et al. Disruption of caveolin1 leads to enhanced nitrosative pressure and severe systolic andRevised: 25 August, 2008 Accepted: 25 August,Current Cardiology Evaluations, 2009, Vol. five, No.[76][67][77] [78][68] [69][79][70] [71][80][72] [73][81] [82][74][83] [84][75]diastolic heart failure. Biochem Biophys Res Commun 2006; 340: 7028. Woodman SE, Park DS, Cohen AW, et al. Caveolin3 HQNO Biological Activity knockout mice develop a progressive cardiomyopathy and show hyperactivation with the p42/44 MAPK cascade. J Biol Chem 2002; 277: 3898897. Feron O, Balligand JL. Caveolins and the regulation of endothelial nitric oxide synthase within the heart. Cardiovasc Res 2006; 69: 78897. GarciaCardena G, Martasek P, Masters BS, et al. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance in the nos caveolin binding domain in vivo. J Biol Chem 1997; 272: 2543740. Patel HH, Tsutsumi YM, Head BP, et al. Mechanisms of cardiac protection from ischemia/reperfusion injury: a part for caveolae and caveolin1. FASEB J 2007; 21(7): 156574. BallardCroft C, Locklar AC, Kristo G, Lasley RD. Regional myocardial ischemiainduced activation of MAPKs is related with subcellular redistribution of caveolin a.